Revolutionizing Discovery of Aptamer Therapeutics

SELEX Platform 2.0


 Reducing SELEX cycles

 Increasing success rate

 No Lead-optimization

Characteristics of Guardian's Therapeutic Aptamers


  • Typically 15-40 nucleotides in length (5-15 KDa)
  • Non-immunogenic
  • Clinically validated
  • Guardian’s fully stabilized aptamers
    • Stable in serum (>120 hours)
    • Stable in gastric acid and intestinal fluid (≥24 hours)

Amenable to chemical conjugation post synthesis (i.e. toxin, half life extension compounds)

  • Site-specific conjugation using NHS-, thiol or Click chemistry
  • Payload Delivery (Toxin, siRNA, etc)
    • 1:1 stoichiometry of conjugation of targeting and payload moieties
    • Per gram of drug there is more payload for ApDC than ADC
  • Half Life extension
    • PEGylated aptamer demonstrates 9-day human half-life
    • Proprietary fatty acid conjugated aptamer >24-hour monkey half-life


  • CMC is a chemical synthesis process allowing for easy and rapid scalable manufacturing
  • No cell line or cell bank involvement
  • Enables a lower cost of goods for conjugates constructs and bispecifics


Aptamer Discovery Technology Timeline



© 2023 Guardian Therapeutics. All rights reserved.

Welcome to the Guardian Therapeutics and Band Therapeutics website. We do not use any cookies or other technologies on this website, except those that are strictly necessary to enable normal functioning of this web page. View our data protection statement.

Guardian Therapeutics
101 Hartwell Avenue
Suite 2
Lexington, MA 02421
+1 (781) 918-6580

General Inquiries:

Business Development Inquiries: